U.S. Food and Drug Administration, Center for Drug Evaluation and Research
FDA Drug Safety Podcasts
FDA Drug Safety Podcasts, produced by FDA's Center for Drug Evaluation and Research, provide emerging safety information about drugs in conjunction with the release of Drug Safety Communications. For more information, please visit: www.fda.gov/drugsafetypodcasts
Koniecznie odwiedź stronę podcastu i wesprzyj twórcę: www.fda.gov
Autor
U.S. Food and Drug Administration, Center for Drug Evaluation and Research
Kategoria
Strona podcastu
Ostatni odcinek
2 sty 2025
Gdzie słuchać?
Podcasty w aplikacji Replaio Radio Już wkrótcePodcasty trafią do aplikacji już wkrótce. Zainstaluj teraz i jako pierwszy zobacz nowe podejście do podcastów
Zainstaluj za darmo
Android prawie 10 mln pobrań · ocena 4,8
iOS niedługo
Odcinki
FDA recommends health care professionals discuss naloxone with all patients when prescribing opioid pain relievers or medicines to treat opioid use disorder 29.07.2020 3:00
Listen to an audio podcast of the 07.23.2020 FDA Drug Safety Communication: FDA recommends HCPs discuss naloxone with all patients when prescribing opioid pain relievers or medicines to treat opioid use disorder
FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems 24.04.2020 3:32
Listen to an audio podcast of the April 24, 2020 FDA Drug Safety Communication: FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems. Close supervision is recommended
FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market 19.02.2020 3:00
Listen to an audio podcast of the February 13 2020 FDA Drug Safety Communicationrequesting the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market. Potential risk of cancer outweighs the benefits.
FDA strengthens warning that untreated constipation caused by schizophrenia medicine clozapine (Clozaril) can lead to serious bowel problems 10.02.2020 3:00
Listen to an audio podcast of the January 28, 2020 FDA Drug Safety Communication that FDA is strengthening an existing warning that constipation caused by the schizophrenia medicine clozapine (Clozaril, Fazaclo ODT, Versacloz, generics) can, uncommonly, progress to serious bowel complications.
Safety clinical trial shows possible increased risk of cancer with weight-loss medicine Belviq, Belviq XR (lorcaserin) 23.01.2020 2:00
Listen to an audio podcast of the January 14, 2020 FDA Drug Safety Communication titled "Safety clinical trial shows possible increased risk of cancer with weight-loss medicine Belviq, Belviq XR (lorcaserin).
Podobne podcasty
Słuchaj podcastu FDA Drug Safety Podcasts w Replaio
Radio i podcasty w jednej aplikacji - za darmo, bez zakładania konta. Zainstaluj już dziś i nie przegap premiery
Replaio nie jest wydawcą podcastów; nazwy audycji, okładki i audio należą do ich autorów i są rozpowszechniane przez publiczne kanały RSS
